Single center single arm clinical prospective study of neoantigen reactive T cells (NRTs) combined with PD-1 inhibitor in the treatment of Chinese patients with advanced refractory solid tumors
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2017
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 01 Aug 2017 Status changed from recruiting to suspended, according to an Incyte Corporation media release.
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.
- 04 May 2017 New trial record